Biogen Inc. (FRA:IDP)
157.05
+1.15 (0.74%)
Last updated: Dec 5, 2025, 5:35 PM CET
Biogen Employees
Biogen had 7,605 employees as of December 31, 2024. The number of employees increased by 35 or 0.46% compared to the previous year.
Employees
7,605
Change (1Y)
35
Growth (1Y)
0.46%
Revenue / Employee
€1,128,096
Profits / Employee
€180,266
Market Cap
22.86B
Employees Chart
Employees History
Related Stocks
| Company Name | Employees |
|---|---|
| SAP SE | 109,121 |
| Siemens Aktiengesellschaft | 318,000 |
| Allianz SE | 156,626 |
| Deutsche Telekom AG | 198,194 |
| Siemens Energy AG | 103,000 |
| Rheinmetall AG | 28,539 |
| Münchener Rückversicherungs-Gesellschaft Aktiengesellschaft in München | 44,224 |
| Deutsche Bank Aktiengesellschaft | 89,753 |
Biogen News
- 2 days ago - BIIB January 2026 Options Begin Trading - Nasdaq
- 2 days ago - Eisai And Biogen Report Long-Term Benefits Of LEQEMBI In Early Alzheimer's Disease - Nasdaq
- 2 days ago - Biogen (BIIB) Reports Promising Lecanemab Findings for Alzheimer's Treatment - GuruFocus
- 2 days ago - Eisai Presents New Data on the Continued and Expanding Benefit of LEQEMBI® (lecanemab-irmb) Maintenance Treatment in Early Alzheimer's Disease at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 - GlobeNewsWire
- 2 days ago - Biogen Inc. (BIIB) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript - Seeking Alpha
- 3 days ago - Biogen (BIIB) Sees Promising Lecanemab Results in Alzheimer's Treatment - GuruFocus
- 3 days ago - New Data Presented at the Clinical Trials on Alzheimer's Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI® (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF - GlobeNewsWire
- 3 days ago - New Data Presented at the Clinical Trials on Alzheimer’s Disease (CTAD) Conference 2025 Confirms Pharmacological Effect of LEQEMBI (lecanemab-irmb) on Neurotoxic Aβ Protofibrils in CSF - Wallstreet:Online